Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma
- PMID: 35929921
- PMCID: PMC8057358
- DOI: 10.5152/tud.2021.21006
Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma
Abstract
Historically, immediate cytoreductive nephrectomy (CN) was considered the standard of care in patients with metastatic renal cell carcinoma (mRCC) who were fit enough to undergo surgery. Recently, 2 randomized controlled trials, SURTIME and CARMENA, have questioned the role of immediate CN and initiated an ongoing debate on the proper indications and timing of CN. Although some patients still benefit from immediate CN, other patients require immediate systemic treatment, and some of them might benefit from deferred CN in the absence of disease progression. This study provides an overview of the history of CN, an in-depth analysis of SURTIME and CARMENA, and highlights the current indications for performing immediate or deferred CN.
Conflict of interest statement
Figures
Similar articles
-
Cytoreductive Nephrectomy and Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives.Medicina (Kaunas). 2023 Apr 15;59(4):767. doi: 10.3390/medicina59040767. Medicina (Kaunas). 2023. PMID: 37109725 Free PMC article. Review.
-
Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?Eur Urol Oncol. 2019 Jul;2(4):365-378. doi: 10.1016/j.euo.2019.04.007. Epub 2019 May 18. Eur Urol Oncol. 2019. PMID: 31109902 Review.
-
Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data.Eur Urol Oncol. 2020 Apr;3(2):168-173. doi: 10.1016/j.euo.2019.12.004. Epub 2020 Jan 16. Eur Urol Oncol. 2020. PMID: 31956080
-
Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial.BJU Int. 2022 Jul;130(1):68-75. doi: 10.1111/bju.15625. Epub 2021 Nov 24. BJU Int. 2022. PMID: 34706141 Clinical Trial.
-
Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.Eur Urol. 2019 Jan;75(1):111-128. doi: 10.1016/j.eururo.2018.09.016. Epub 2018 Oct 25. Eur Urol. 2019. PMID: 30467042
Cited by
-
Mitochondrially targeted tamoxifen as anticancer therapy: case series of patients with renal cell carcinoma treated in a phase I/Ib clinical trial.Ther Adv Med Oncol. 2023 Sep 30;15:17588359231197957. doi: 10.1177/17588359231197957. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37786538 Free PMC article.
-
Cytoreductive Nephrectomy and Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives.Medicina (Kaunas). 2023 Apr 15;59(4):767. doi: 10.3390/medicina59040767. Medicina (Kaunas). 2023. PMID: 37109725 Free PMC article. Review.
-
Survival benefits of Cytoreductive Nephrectomy in patients with metastatic renal cell carcinoma: evidence from a SEER-based retrospective cohort study.PLoS One. 2025 Jul 15;20(7):e0318896. doi: 10.1371/journal.pone.0318896. eCollection 2025. PLoS One. 2025. PMID: 40663535 Free PMC article.
-
Revisiting Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Evidence of Survival Benefit with First-Line Immunotherapy and Targeted Therapy Regimens.J Clin Med. 2025 Aug 6;14(15):5543. doi: 10.3390/jcm14155543. J Clin Med. 2025. PMID: 40807168 Free PMC article.
-
The role of cytoreductive nephrectomy in the treatment of patients with metastatic kidney cancer - review article.Contemp Oncol (Pozn). 2023;27(3):132-138. doi: 10.5114/wo.2023.133258. Epub 2023 Nov 27. Contemp Oncol (Pozn). 2023. PMID: 38239866 Free PMC article. Review.
References
-
- Thorstenson A, Bergman M, Scherman-Plogell AH, Hosseinnia S, Ljungberg B, Adolfsson J, et al. Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005–2010: a population-based study from the national Swedish kidney cancer register. Scand J Urol. 2014;48:231–8. doi: 10.3109/21681805.2013.864698. - DOI - PubMed
-
- Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, et al. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncol. 2019;5:164–70. doi: 10.1001/jamaoncol.2018.5543. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources